Empagliflozin has shown early and sustained improved quality of life (at least for a year) in patients with cardiac failure and preserved function. Patients with cardiac failure and preserved ejection fraction present a deteriorated quality of life. The EMPEROR-Preserved assessed the efficacy of Empagliflozin in several baseline health status assessments. HRQoL was measured using the...
01- Management of Abdominal Aortic Aneurysms in 2021 Abdominal aortic aneurysms (AAA) are those of >3 cm aortic diameter. They run the risk of rupture and ensuing death by bleeding. In consequence, they are treated to repair the aneurysm before it ruptures. Read more HERE 02- Ten Commandments for 2021 Guidelines on Valvular Heart Disease Since...
In low-risk patients, there was a very low incidence of greater than moderate leak, including in patients with minimal oversizing. The degree of prosthesis oversizing had a great impact on mild paravalvular leak reduction and the need for post-dilation without changing valve hemodynamics. This research investigated the impact of the perimeter and the area, measured...
The Swan Ganz catheter has been used in the clinical practice for years. However, its usefulness remains under discussion and its use keeps dropping. A new analysis published in JAHA might bring it back at least in the context of cardiogenic shock, where it showed improved prognosis and more effective complexity management. Recently, the lack...
According to this new meta-analysis (presented at AHA 2021 and published in The Lancet), mortality is similar between surgery and angioplasty to treat left main coronary artery in patients with simple or intermediate anatomy. This new study estimates that, after 5 years, mortality with surgery would be 11.2% vs. 10.2% with angioplasty, a non-significant difference. This debate...
Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the...
Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to the consensus that beyond the “category” of bleeding or ischemic risk, what is most important is a decision tailored to the patient being treated. DAPT duration should be individual, instead of standardized by a risk score. In the...
Compared with visual estimation of lesions, using quantitative angiography-derived fractional flow reserve (quantitative flow ration, QFR) provides better clinical outcomes at one year for angioplasty. These results emerge from the Chinese FAVOR III study, presented at the 2021 TCT scientific sessions and simultaneously published in The Lancet. The simplicity and safety offered by QRF—since there is...
Angioplasty could not reach non-inferiority to surgery to treat patients with three-vessel lesions. In this head-to-head study of both revascularization strategies in patients with three-vessel coronary disease, fractional flow reserve (FFR)-guided angioplasty could not reach the performance of myocardial revascularization surgery in relation to a composite of adverse events. The FAME 3 study was presented during...
The 5-year followup of the iFR-SWEDEHEART has confirmed the safety and efficacy of using either FFR or iFR to guide PCI in intermediate lesions. The iFR-SWEDEHEART initial outcomes together with the DEFINE-FLAIR outcomes had started the debate around these two measuring strategies. The FFR requires adenosine, which results costly in addition to causing adverse events,...